The Drug Research War
“Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which is the heart of pharmaceutical and biotech companies, is growing at a yearly clip of 15% to 20%. Right now the lion’s share of the work has gone to U.S. companies that focus on drug research for giants like Pfizer. But now, India and China are angling to get a piece. “
Biotechs struggle as IPOs find cool reception
“Five initial public offerings had trading debuts Thursday, bringing mixed results and a message that biotech certainly isn’t what the doctor ordered for the IPO market. “
The Health-Care Catastrophe That Won’t Happen
Why biotech gains will rein in medical costs. The lesson of info tech
Will U.S. try to circumvent drug firms patent?
The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.
Another gene genie out of the bottle
The European Commission has lifted a five-year moratorium on genetically modified produce, by allowing the sale in Europe of one type of modified corn. But the battle by producers of such crops to win governments� and consumers� acceptance is far from over
Could patients glean stock tips?: Drug trial participants may be insider trading.
“Patients in clinical trials might be using information about the drug they are taking to trade illegally in pharmaceutical stocks, warns a group of doctors and bioethicists. But they have no idea how prevalent the problem might be.”
Financial Snapshot For March 2004: Looking Good
“It’s been a rocky first quarter for the biotech stocks � and for the markets in general. Yet, despite investors’ nervousness � about issues as diverse as the terrorist train bombing in Madrid and the departure of Mark McClellan from the FDA � the biotech sector managed to hold its own, and even out-performed the Nasdaq Composite Index.”